aBLA Filing Intelligence & Biosimilar Opportunity

Talvey

Talquetamab-Tgvs

Anticancer

Subcutaneous Injection

Talvey is a bispecific antibody injection for adults with multiple myeloma who have already tried at least four other treatments. It helps the immune system target and kill myeloma cells.

Approval Date

09-Aug-23

Data Exclusivity Expiry

09-Aug-27

Market Exclusivity Expiry

09-Aug-35

Commercial snapshot

Market performance & projections

Revenue ($M)

463

CAGR (%)

0.3865

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

762

2027

1079

2028

1392

2029

1711

2030

1959

2031

2164

2032

2386

Molecule profile

Details & specifications

Molecule

Talquetamab-Tgvs

Innovator

JANSSEN BIOTECH, INC.

Dosage Form

Subcutaneous Injection

Strength

2 mg/mL and 40 mg/mL

Therapeutic Category

Anticancer

Usage

To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.